top of page

PIPELINE
Developing innovative treatments
for rare CNS disorders
Our programs target rare CNS and neurodevelopmental disorders through novel mechanisms of action.

June 2026 pipeline update.png

LEAD PROGRAMS

CSTI-500 is a serotonin-preferred triple monoamine reuptake inhibitor (TRI) that inhibits SERT, DAT, and NET, thereby modulating serotonin, dopamine, and norepinephrine signaling. “Serotonin-preferred” means that CSTI-500 has greater potency at SERT than at DAT and NET, producing broader monoamine modulation as concentrations rise. These systems are involved in behavioral and emotional regulation, reward, attention, motivation, and feeding-related behavior

Multiple lines of evidence implicate dysregulated monoamine signaling in the behavioral and feeding-related symptoms of PWS. Based on this rationale, CSTI-500 is being evaluated as a single-molecule approach to behavioral dysregulation and hyperphagia. CSTI-500 is investigational. Initial safety, tolerability, and pharmacokinetic data have been generated in completed studies involving healthy volunteers and individuals with PWS; longer-term safety and clinical efficacy in PWS remain to be established in clinical trials.

CSTI-500: A Serotonin-Preferred, Tunable Triple Monoamine Reuptake Inhibitor in Phase 2 Clinical Development

CSTI-100 / HBS-102

MCHR1 antagonist for the treatment of rare neurological disorders.

bottom of page